Clinical trials: Psychosis Nos/Other
First Episode Psychosis (FEP)
Dopamine and Insulin in Psychosis
Patients with schizophrenia have a high risk of developing metabolic disorders and current evidence points to an overlap in mechanisms underlying psychiatric symptoms and metabolic disturbances.
- Trial name
- DIPS (NCT07252752)
- Testing
- Intranasal Insulin, Low dose insulin infusion, [11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)
- Where
- Austria
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Schizophrenia
Fingolimod in Schizophrenia Patients
This will be a single site safety and proof of concept study conducted at the Indiana University Psychotic Disorders Program. Forty subjects with schizophrenia or schizoaffective disorders will be randomized 1:1 to double-blind…
- Trial name
- STEP (NCT01779700)
- Testing
- Fingolimod
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Indiana University
Psychotic Disorder, Schizophreniform Disorder
Study of Amantadine for Weight Stabilization During Olanzapine Treatment
Weight gain associated with antipsychotic medication use is a major side effect that limits the tolerability of these drugs. This often significant weight gain adversely affects health, increasing risks for developing…
- Conditions
- Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00287352
- Testing
- Olanzapine, Amantadine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.
This application seeks renewed support for MH59803, "Dopaminergic substrates of startle gating across species," to extend a clear path of "bench-to-bedside" progress towards a critical paradigm shift in therapeutic models for…
- Trial name
- NCT02634684
- Testing
- Dextroamphetamine
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Psychosis, Medication Adherence
Piloting MOL Intervention for Neuroleptic Decision Making
The aim of the current study is to pilot a novel intervention to help people explore their decision making around the use of neuroleptic medication.
- Trial name
- NCT03537040
- Testing
- Method of Levels
- Where
- 2 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- University of Manchester
Psychosis, First Episode Psychosis
Thermoregulation Among Individuals With First-episode Psychosis
The project will evaluate thermoregulatory processes among individuals with and without first-episode psychosis.
- Trial name
- NCT04369677
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Nicholas Breitborde
Schizophrenia, Psychosis
Searching for Early Biomarkers of Long-term Hepatic, Metabolic and Endothelial Dysfunction in Non-affective Psychosis
This study aims to evaluate, at long-term, the occurrence of liver disease and cardio-vascular risk, in a sample of patients diagnosed with first episode of non-affective psychosis.
- Conditions
- Schizophrenia, Psychosis, Metabolic Syndrome
- Trial name
- NCT03481465
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Fundación Marques de Valdecilla
Clinical High Risk for Psychosis (CHR), Suicidal Ideation
Developing a Recovery-Oriented Suicide Prevention Program for Young People at Clinical High Risk for Psychosis
Young people at clinical high risk for psychosis are more likely to experience suicide thoughts than the general population, but there are few suicide prevention programs designed specifically for them.
- Conditions
- Clinical High Risk for Psychosis (CHR), Suicidal Ideation, Psychosis, Suicidal Behavior
- Trial name
- NCT07756567
- Testing
- Suicide Prevention Intervention, Standard Care (in control arm)
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- University of California, San Diego
Schizophrenia, Schizoaffective Disorder
Effect of Neuroplasticity Modulation in tDCS Treatment Response Among Schizophrenia Patients With Auditory Hallucination
Schizophrenia is a severe neuropsychiatric disorder of the brain and is also one of the top ten disabling diseases. A common symptom of schizophrenia (SCZ) is hearing voices inside one's heads which others do not.
- Trial name
- NCT04629352
- Testing
- Verum Accelerated Transcranial Direct Current Stimulation (acctDCS)
- Where
- India
- Volunteers
- 72 people
- Sponsor
- National Institute of Mental Health and Neuro Sciences, India
Psychotic Disorders
Antipsychotic to Treat Psychosis Syndrome
This study assess the safety and effects of atypical antipsychotics in subjects with psychosis syndrome and psychosis risk syndrome.
- Trial name
- NCT02137616
- Testing
- risperidone, olanzapine, Quetiapine
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Central South University
Psychosis; Acute
Cerebellum-based Imaging Neural Markers for Antipsychotic Response
This study plans to collect 120 patients with first-episode psychosis. Participants will receive multimodal MRI scans (naturalistic fMRI, structural, diffusional) and comprehensive clinical assessments at baseline, and…
- Trial name
- CINEMA (NCT07483294)
- Testing
- risperidone, aripiprazole
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Northwell Health
Psychotic Disorder
The Effect of D-serine as add-on Therapy in Recent-onset Psychosis
In psychotic disorders, negative symptoms and cognitive impairment are difficult to treat with antipsychotics, which are mostly effective for positive symptoms.
- Trial name
- DROP (NCT04140773)
- Testing
- D-serine
- Where
- Switzerland
- Volunteers
- 3 people
- Sponsor
- Dragos Inta
Schizo Affective Disorder, Schizophrenia
L-arginine Study for Persistent Symptoms of Schizophrenia
The purpose of this research is to see if daily combination treatment of L-arginine and Kuvan changes brain chemistry in people experiencing schizophrenia as measured by MRS brain scans.
- Trial name
- NCT04054973
- Testing
- L-arginine, Sapropterin Dihydrochloride
- Where
- United States
- Sponsor
- University of Massachusetts, Worcester
Psychosis, Schizophrenia
ReMindCare App for Patients From First Episode of Psychosis Unit.
ReMindCare is an app designed by the Unit of Psychiatry at the Clinical Hospital of Valencia in liaison with the Polytechnic University of Valencia.
- Conditions
- Psychosis, Schizophrenia, Psychotic Disorders, Delirium
- Trial name
- NCT03807388
- Testing
- ReMindCare Intervention Group, Treatment as Usual
- Where
- Spain
- Volunteers
- 140 people
- Sponsor
- Instituto de Investigacion Sanitaria INCLIVA
Schizophrenia, Psychoses
Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis
The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used.
- Trial name
- NCT00204061
- Testing
- Supportive management, Amisulpride
- Where
- Germany
- Volunteers
- 124 people
- Sponsor
- University of Cologne
Schizophrenia Spectrum and Other Psychotic Disorders
Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial
The aim of this study is to explore new safe effective psychotherapeutic interventions for schizophrenia through assessing the efficacy and acceptability of complementary "Insight Enhancement Program" (IEP) and "Metacognitive…
- Trial name
- NCT03955549
- Testing
- Insight Enhancement Program (IEP), Metacognitive Training for Psychosis (MCT), Treatment As Usual (TAU)
- Where
- Egypt
- Volunteers
- 99 people
- Sponsor
- Agiad Psychiatry Hospital
Depression, Psychosis
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
This proposal will examine the effects of estradiol administration on perimenopausal-onset (PO) anhedonia and psychosis symptoms as well as on brain function using simultaneous positron emission tomography and functional magnetic…
- Conditions
- Depression, Psychosis, Anhedonia
- Trial name
- PEEPS (NCT05282277)
- Testing
- Transdermal Estradiol, Micronized Progesterone, Raclopride C11
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizotypal Disorder
The OPUS YOUNG Trial. Early Intervention Versus Treatment as Usual for Adolescents With First-episode Psychosis
The OPUS YOUNG (OY) study investigates the efficacy of early intervention service versus treatment as usual (TAU) for adolescents aged 12-17 years with a first-episode psychosis.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Acute and Transient Psychotic Disorder, Unspecified
- Trial name
- OPUS-YOUNG (NCT04916626)
- Testing
- OPUS YOUNG, Treatment as Usual
- Where
- Denmark
- Volunteers
- 284 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Bipolar Affective Disorder, Schizophrenia Disorders
Medical Phenotyping of NHS General Adult Psychiatry (GAP) Inpatients
This observational study will characterise the general psychiatric and general medical phenotypes of 100 adults, sequentially admitted to NHS General Adult Psychiatry (GAP) "mental health" inpatient wards, providing the first…
- Conditions
- Bipolar Affective Disorder, Schizophrenia Disorders, Depression Disorders, Personality Disorders
- Trial name
- NCT07398365
- Testing
- Questionnaires, rating scales, & review of notes
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University of Edinburgh
Psychosis, Social Behavior
Virtual Reality Assisted CBT for Social Difficulties: a Feasibility Study in Early Intervention for Psychosis Services
People experiencing psychosis might find social interactions stressful and avoid them. This can result in isolation and can affect relationships, employment and quality of life.
- Conditions
- Psychosis, Social Behavior, Paranoia, Social Anxiety
- Trial name
- NCT04310475
- Testing
- Virtual reality assisted CBT
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- King's College London